Pancreatic Disorders & Therapy
Open Access

Pancreatic cancer and genetics: Where are we heading to?

International Conference on Pancreatic Disorders and Treatment

October 17-19, 2016 Chicago, USA

Mizrahi Meir

Harvard Medical School, USA

Posters & Accepted Abstracts: Pancreat Disord Ther

Abstract :

The incidence of pancreas cancer ranges between 1 to 10 cases per 100,000 persons. The incidence rate is higher in Western countries like the United States. Approximately 40,000 persons died from pancreas cancer in 2014 in the United States, making this the 4th most common cause of cancer death in women and men. Only 20% of patients with PC present at diagnosis time with localized disease that can be treated surgically, but the overall 5 years survival is 6% even for the patient who underwent surgical resection. In patients with first degree relative with PC the risk for developing PC increased by factor of 2, 6 and 30 for 1, 2 or 3 first degree relatives respectively. Breast and ovarian cancer syndrome is caused by mutation in different genes such as: BRCA1, BRCA2, PALB2 and ATM. BRCA1 and BRCA2 also increase the risk for prostate cancer and PC by 4-7 folds for patients carrying the mutation. Furthermore carriers of DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 and PMS2 have increased risk to develop PC 8 times more compared to the general population. Other Genes that play role in other familial syndromes also were found to increase the risk of PC such as: APC, CDK2NA (P16), PRSS1; STK11and TP53. Identifying germ-line mutations that increase the risk of pancreas cancer has substantial benefits for both patient and their unaffected relatives. Pancreas cancer patients with BRCA1 and BRCA2 mutations are more likely to benefit from PARP inhibitors and platinum-based chemotherapy compared with those without mutations.

Biography :

Email: mmizrahi@bidmc.harvard.edu